About 1,000 U.S. patients are diagnosed each year with Large Granular Lymphocyte (LGL) leukemia, a chronic condition in which a person’s white blood cells clone themselves and multiply, attacking the bone marrow and joints. While there is no cure for the disease, many patients can manage their condition with immunosuppressant therapies.
UVA Cancer Center's LGL Leukemia Program offers patients access to the most advanced research-based treatment options available. Led by UVA Cancer Center Director Dr. Tom Loughran, who discovered the disease more than 30 years ago, the program includes a clinic, patient registry, and dedicated research laboratory.
Dr. Loughran’s research team focuses on identifying the genetic changes that drive the development and persistence of LGL leukemia. The team is engaged in comprehensive, whole genome sequencing to identify new targets for future clinical trials and possibly a cure for the disease.
We need your help. Your donation today will speed advances that will benefit not only LGL leukemia patients, but leukemia patients worldwide.
To learn more about UVA’s LGL leukemia program, visit: UVA’s LGL Leukemia Program Webpage
If you are interested in other giving opportunities supporting LGL leukemia, including automatic monthly or annual gifts, please contact Jocelyn Lewis at email@example.com.